Physician profile
Joel D Kavan
NPI 1497749295
$1,861.69
in general payments reported to CMS, 2019-2025
15 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $149 · 2021: $489 · 2022: $437 · 2023: $245 · 2024: $218 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $559.95 | 2020-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $332.16 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $148.06 | 2022-2025 | |
| Biogen, INC. | $138.65 | 2021-2022 | |
| Mylan Specialty L.P. | $117.14 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $110.21 | 2021-2024 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $106.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $104.70 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $97.86 | 2021-2022 | |
| Exact Sciences Corporation | $48.67 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $24.19 | 2019 | |
| Amarin Pharma, INC. | $24.17 | 2021 | |
| Dermira, INC. | $19.50 | 2020 | |
| Pfizer INC. | $16.72 | 2024 | |
| Sanofi Pasteur INC. | $13.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Kavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.